Supply Chain Intelligence

Sutro Biopharma, Inc. Supply Chain

STRO supply chain intelligence for Sutro Biopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

STRO ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
5Customers
3Debt Items
20Related Chains

Sutro Biopharma, Inc. Suppliers

TickerNameConfidenceEvidence
TD-SECURITIES-USA-LLC TD-SECURITIES-USA-LLC 92% On February 9, 2026, Sutro Biopharma, Inc. entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein
VAXCYTE VAXCYTE 90% In May 2018, we entered into a Supply Agreement with Vaxcyte, wherein Vaxcyte engaged us to supply extracts and custom reagents, as requested by Vaxcyte.
PCVX Vaxcyte, Inc. 72% Reciprocal relationship from PCVX graph: rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturi…

Sutro Biopharma, Inc. Customers

TickerNameConfidenceEvidence
BX Blackstone Inc. 90% In June 2023, we entered into a purchase and sale agreement with Blackstone, or the Blackstone Agreement, to sell to Blackstone a revenue interest in our 4% royalty on potential future sales of Vaxcy…
BX Blackstone Inc. 90% Reciprocal relationship from BX graph: Reciprocal relationship from STRO graph: Reciprocal relationship from BX graph: Reciprocal relationship from STRO graph: Reciprocal relationship from BX graph: …
VAXCYTE VAXCYTE 90% In November 2023, or the Exercise Date, Vaxcyte exercised the Option by submitting written notice thereof to us and concurrently paid us $50.0 million in cash as the first of two installment payments…
TASLY TASLY 85% In December 2021, we entered into the Tasly License Agreement with Tasly to grant an exclusive license to develop and commercialize STRO-002 in Greater China.
PCVX Vaxcyte, Inc. 72% Reciprocal relationship from PCVX graph: rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturi…

Sutro Biopharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
STRO-DEBT-12802 Warrants outstanding: 734000 90% xbrl warrant detail from xbrl 2018-12-31.
STRO-DEBT-12803 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
STRO-DEBT Debt stack $13.6M 90% Market cache reports total debt of $13.6M.

Sutro Biopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Sutro Biopharma, Inc..

Sutro Biopharma, Inc. Ownership

HolderNameConfidenceEvidence
STRO-OWNER-BARCLAYS-PLC BARCLAYS PLC 90% 13F overlay lists BARCLAYS PLC as top holder; 12 tracked holders.

Sutro Biopharma, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BNTC Benitec Biopharma Inc. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
PSNL Personalis, Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
View STRO supply chain intel →

Explore the full interactive supply chain map for Sutro Biopharma, Inc..

Open STRO supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map